Breast cancer: pertuzumab-related diarrhea is common, but manageable

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • In both metastatic and early-stage HER2+ breast cancer treated with pertuzumab (Perjeta), the incidence of diarrhea is high (28%-72%), but dose-delays or discontinuations resulting from diarrhea are rare.

Why this matters

 

 

  • This study gives clinicians and patients information about the frequency and severity of diarrhea as an adverse effect of pertuzumab.

Study design

 

 

  • This study was a pooled analysis of a phase 3 trial of metastatic HER2+ cancer (CLEOPATRA, n=804) and 2 phase 2 trials (NeoSphere, n=416; TRYPHAENA, n=223).
  • Funding:  Genentech

Key results

 

 

  • Pertuzumab-based treatment had a high incidence of diarrhea (from 28% to 72%; grade 1, 21%-54%; grade 2, 8%-37%; grade 3, 0%-12%; grade 4, 0%).
  • The incidence was greatest during the first cycle, but decreased with later cycles.
  • 0%-8% had dose delays or discontinuations from diarrhea.
  • The most common treatment for pertuzumab-related diarrhea was loperamide.
  • The highest incidence of all-grade diarrhea was seen in pertuzumab-treated Asian vs white patients with metastatic breast cancer (74% vs 63%) compared with 53% vs 45% of control patients.

Limitation

 

 

  • Lack of participation by patients with stage III tumors.